StockData
Merck & Co., Inc. logo

Merck & Co., Inc. (MRK) operating KPIs

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$146.33+5.40 (+3.83%)

Close on Oct 29, 2026Market cap $361.02BP/E 117.1Yield 2.24%

Merck belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. sales ($M) ($M)

Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b

QuarterlyAnnual
Latest, Q4 2025
22
Period ended Dec 31, 2025
Change on a year earlier
+15.8%
19 in Q4 2024
History
36 quarters
Since Q1 2017
Sources
27
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedBelsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. sales ($M) ($M)Year on yearSource
Q4 2025Dec 31, 202522+15.8%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202528+40.0%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2025Jun 30, 202518-5.3%Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2025Mar 31, 202513-13.3%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2024Dec 31, 202419-9.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 202420-13.0%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 202419-9.5%Form 8-K (tm2521736d1_ex99-1.htm, filed 2025-07-29) ↗
Q1 2024Mar 31, 202415-6.2%Form 8-K (tm2512885d1_ex99-1.htm, filed 2025-04-24) ↗
Q4 2023Dec 31, 202321+10.5%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202323+15.0%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 202321+10.5%Form 8-K (tm2420272d1_ex99-1.htm, filed 2024-07-30) ↗
Q1 2023Mar 31, 202316-20.0%Form 8-K (tm2412490d1_ex99-1.htm, filed 2024-04-25) ↗
Q4 2022Dec 31, 202219-13.6%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202220-13.0%Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗
Q2 2022Jun 30, 202219+35.7%Form 8-K (tm2322190d1_ex99-1.htm, filed 2023-08-01) ↗
Q1 2022Mar 31, 202220+11.1%Form 8-K (tm2213615d1_ex99-1.htm, filed 2022-04-28) ↗

Breakdown

What makes up belsomra (suvorexant — insomnia orexin receptor antagonist) — u.s. sales ($m)

Cite this data

StockData. (2026). Merck Belsomra (suvorexant — insomnia orexin receptor antagonist) — U.S. sales ($M) ($M), quarterly Q1 2017–Q4 2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev_belsomra_us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.